"Drug Interactions" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The action of a drug that may affect the activity, metabolism, or toxicity of another drug.
| Descriptor ID |
D004347
|
| MeSH Number(s) |
G07.690.773.968
|
| Concept/Terms |
Drug Interactions- Drug Interactions
- Drug Interaction
- Interaction, Drug
- Interactions, Drug
|
Below are MeSH descriptors whose meaning is more general than "Drug Interactions".
Below are MeSH descriptors whose meaning is more specific than "Drug Interactions".
This graph shows the total number of publications written about "Drug Interactions" by people in this website by year, and whether "Drug Interactions" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2002 | 1 | 1 | 2 |
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 2 | 3 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 3 | 3 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 7 | 8 |
| 2017 | 13 | 63 | 76 |
| 2018 | 7 | 64 | 71 |
| 2019 | 7 | 21 | 28 |
| 2020 | 5 | 39 | 44 |
| 2021 | 1 | 18 | 19 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Interactions" by people in Profiles.
-
Adverse effects, pharmacological interactions, and cardiovascular drugs in COVID-19 treatment. Arch Cardiol Mex. 2021 Dec 20; 91(Suplemento COVID):079-085.
-
Long-term olfactory dysfunction following coronavirus disease 2019 infection, routine neck dissection at salvage laryngectomy, parotid incidentalomas, and prescribing intranasal steroids in HIV infection. J Laryngol Otol. 2021 Sep; 135(9):753-754.
-
Adverse drug event risk assessment by the virtual addition of COVID-19 repurposed drugs to Medicare and commercially insured patients' drug regimens: A drug safety simulation study. Clin Transl Sci. 2021 09; 14(5):1799-1809.
-
Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions. Expert Rev Hematol. 2021 09; 14(9):819-830.
-
Heterogeneous graph attention networks for drug virus association prediction. Methods. 2022 02; 198:11-18.
-
Potential clinically significant drug-drug interactions of hydroxychloroquine used in the treatment of COVID-19. Int J Clin Pract. 2021 Nov; 75(11):e14710.
-
Severe acute respiratory syndrome coronavirus 2 vaccination and cancer therapy: A successful but mindful mix. Eur J Cancer. 2021 10; 156:119-121.
-
Inherent Dangers of Using Non-US Food and Drug Administration-Approved Substances of Abuse. J Clin Pharmacol. 2021 08; 61 Suppl 2:S129-S141.
-
Severe Inflammation, Acute Kidney Injury, and Drug-Drug Interaction: Triple Penalty for Prolonged Elimination of Apixaban in Patients With Coronavirus Disease 2019: A Grand Round. Ther Drug Monit. 2021 08 01; 43(4):455-458.
-
Drug interaction profile of TKI alectinib allows effective and safe treatment of ALK+ lung cancer in the kidney transplant recipient. Int Immunopharmacol. 2021 Oct; 99:108012.